All In Biotech

Drug Trial Radar · NCT05271370

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

56

Actual

Start

Aug 29, 2017

Primary completion

Jun 20, 2022

Study completion Jul 10, 2022

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC (subcutaneous) monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects. Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one-week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.

Conditions

  • HIV-1-infection

Interventions

  • PRO 140 350Drug

    Pro140 SC injection 350 mg

  • PRO 140 525Drug

    525 mg

  • PRO 140 700Drug

    700 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
  2. Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quest Clinical Research

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.